Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

NovoCure Limited (NVCR) Guidance & Earnings Results

On 2026-07-23 NovoCure Limited raised guidance: "FY26 total net revenue raised to $710M-$725M from $690M-$710M; FY26 Adjusted EBITDA raised to $0M-$15M from $(15)M-$0M; Optune Lua and Optune Pax collective net revenue guidance…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

NVCRNovoCure LimitedFollow NVCR — free
Medical Devices · Healthcare
—
Price chart with a free account
Market cap
1.7B
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
29 Oct, in 5 days

What management guided

each earnings 8-K · figures checked against the filing text
ReleaseDirectionWhat they said
23 Jul 26RaisedFY26 total net revenue raised to $710M-$725M from $690M-$710M; FY26 Adjusted EBITDA raised to $0M-$15M from $(15)M-$0M; Optune Lua and Optune Pax collective net revenue guidance $20M-$30M · full year
30 Apr 26RaisedTotal net revenue $690-710M; Adjusted EBITDA $(15)-$0M · full year

NovoCure Limited — questions

What guidance did NovoCure Limited give?
On 2026-07-23: "FY26 total net revenue raised to $710M-$725M from $690M-$710M; FY26 Adjusted EBITDA raised to $0M-$15M from $(15)M-$0M; Optune Lua and Optune Pax collective net revenue guidance $20M-$30M"
When does NovoCure Limited report earnings?
NovoCure Limited's next earnings report is expected on 2026-10-29.

Every figure on this page comes from NovoCure Limited's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.